C-CAR168
unknown (auto-discovered: gene-epigenetic-therapy)
Classification
Biologic
Regulatory Status
investigational; registered trials: NCT07854483 (PHASE1)
Unofficial source
Sources
1
Review
pending review
Overview
Unknown — C-CAR168 was found by open discovery on 2026-10-26 and has not been researched yet.
Evidence and limitations
Known
n/a
Unknown
- Mechanism, dosing, safety, interactions and efficacy are unknown until research runs on this auto-discovered draft.
Study details: trial conditions, not guidance
These are the conditions researchers used in a controlled trial with medical supervision. They aren't instructions.
Doses found
Doses as found in each source, with its grade. What was found, not a direction.
Studies, trials and professional sources
n/a
Reddit, Facebook, Instagram, forums and blogs
n/a
Claims and grades
- Not gradedC-CAR168 is being studied in a registered trial: C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy (NCT07854483; PHASE1; NOT_YET_RECRUITING; sponsor AbelZeta Inc.; intervention "C-CAR168" (BIOLOGICAL)).
Sources (1)
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy (opens in a new tab) · ClinicalTrials.gov · trial-registry · 2026-10-02
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw